Quarterly ResultAug 10, 2026, 08:44 AM
AIM ImmunoTech Completes Pancreatic Cancer Phase 2 Dosing; Q2 Net Loss $(3.8)M
AI Summary
AIM ImmunoTech Inc. reported financial results for the second quarter ended June 30, 2026, alongside a significant business update. The company announced the completion of patient enrollment and Ampligen dosing in its Phase 2 DURIPANC study for metastatic pancreatic cancer, with key data anticipated in Q1 2027 and Q3 2027. For Q2 2026, AIM reported a net loss of $(3.8) million, or $(0.43) per share, but strengthened its balance sheet to $9.9 million in cash and regained full compliance with NYSE American listing standards. The company is also planning for a pivotal Phase 3 trial and exploring non-dilutive funding for Ebola initiatives.
Key Highlights
- Completed patient enrollment and Ampligen dosing in Phase 2 DURIPANC study for metastatic pancreatic cancer.
- Anticipates DURIPANC clinical benefit data in Q1 2027 and Overall Survival data in Q3 2027.
- Ended Q2 2026 with $9.9 million in cash and cash equivalents, up from $3.0 million in Dec 2025.
- Reported Q2 2026 net loss of $(3.8) million, or $(0.43) per share.
- Q2 2026 R&D expenses were $589,000, down from $1.2 million in Q2 2025.
- Regained full compliance with NYSE American continued listing standards.
- Engaged PPD clinical research for planned pivotal Phase 3 trial design.
Price Impact
More from AIM